Neurocrine Bio. (NBIX) PT Raised to $135 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
August 1, 2018 7:16 AM EDTNeedham & Company raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $125.00 (from $110.00) while maintaining a Buy rating.
Analyst Alan Carr commented, "Neurocrine reported $96.9M in 2Q18 Ingrezza sales, above our $85.0M and consensus $84M ests. Mgmt still not providing sales guidance, but... More
Neurocrine Bio. (NBIX) PT Raised to $131 at Baird
August 1, 2018 6:58 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
July 31, 2018 4:04 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.07), $0.10 better than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More